Introduction
Obesity, chronic disorder, obesity, DM-II, SAH, diabetes mellitus, MetS, hypertriglyceridemia, metabolic syndrome, cardiometabolic
OBESITY, CHRONIC DISORDER, OBESITY, CARDIOVASCULAR DISEASE, DIABETES MELLITUS, INSULIN RESISTANCE, HYPERTRIGLYCERIDEMIA, METABOLIC SYNDROME
Obesity is a complex and multifactorial chronic disorder frequently refractory to treatment and prediposing towards the development of cardiometabolic conditions, such as cardiovascular disease (CD), type-II diabetes mellitus (DM-II), systemic arterial hypertension (SAH), metabolic syndrome (MetS) and other comorbiditiesMetS, a systemic proinflammatory condition, involves a set of complex metabolic changes, such as insulin resistance, central obesity, SAH, hypertriglyceridemia and reduced HDL cholesterol levels. Due to its close association with CD and DM-II, MetS is considered a major public health problem worldwideLiraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist 97% similar to native GLP-1Due to its direct implication for the metabolism, body composition should be determined before initiating treatment of obesityFew studiesIn this study, we evaluated the effect of 6 months of treatment with liraglutide on the clinical, laboratory and BIA parameters of adult patients diagnosed with obesity and MetS, stratified by sex, compared to a control group receiving sibutramine.